In line with our hypothesis, we observed severe, widespread inflammation in the colon along with increased incidence of colon polyps/tumors in the Gpr15-KO group compared to Gpr15-Het group in both early and late phases of disease development (Day 24-66) post AOM-DSS administration (Figure 3B; Supplementary Figure 6A). Here, GPR15 is linked to intestinal disorder.